AUL
REGN icon

AlphaGrep UK Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

AlphaGrep UK Ltd’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Buy
284
+10
+4% +$7.66K 0.06% 683
2025
Q4 		$211K Buy
+274
New +$186K 0.07% 607

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AlphaGrep UK Ltd's REGN Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Regeneron Pharmaceuticals (REGN) stake by 3.6% in Q1 2026, buying an estimated $7.66K and bringing the position to 284 shares worth $219K. The position accounts for 0.06% of the portfolio, ranked #683.

AlphaGrep UK Ltd first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. 1,398 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • AlphaGrep UK Ltd held 284 shares of Regeneron Pharmaceuticals worth $219K as of Q1 2026.
  • AlphaGrep UK Ltd bought 10 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.66K.
  • Regeneron Pharmaceuticals made up 0.06% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #683 holding.
  • AlphaGrep UK Ltd first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,398 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.